Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Provided By GlobeNewswire
Last update: Apr 25, 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events
BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines
Read more at globenewswire.com0.323
+0.03 (+8.39%)
Find more stocks in the Stock Screener
BOLT Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
